A crusading scientist identifies a potential public health threat and uses the internet to get access to a cache of data from several studies. After a quick analysis of the pooled data, he reports a previously unrecognized adverse effect of a widely used drug. Patients and physicians become alarmed, and the drug is pulled from the market. Sound like the plot of a new medical thriller? In fact, a similar scenario has hit the headlines several times in the last 10 years. Each time, controversy about the validity of the analysis and conclusions was loud and lasting.
Simulation of Cilostazol Absorption and Pharmacokinetics
Cilostazol absorption and pharmacokinetics were simulated using GastroPlus™. The program’s Advanced Compartmental and Transit (ACAT) model described the absorption of the drug, while pharmacokinetics was…
Physiologically Based Model for Ketoconazole Disposition and Prediction of its Drug-Drug Interactions
Ketoconazole is a potent inhibitor of the major drug-metabolizing enzyme, CYP3A4 and, as the result of that, is involved in many drug-drug interactions. Pharmacokinetic (PK) information available for…
Simulations Plus Releases ClassPharmer Version 4.7
Numerous Data Mining and Drug Design Capabilities Added
Forensic Pharmacometrics: Part 1 – Data Assembly
Pharmacometric modeling and simulation (M&S) is moving from merely describing pharmacokinetic (PK) and pharmacodynamic (PD) phenomena to informing critical drug development and regulatory decision-making…
Population PK/PD Modeling of Efficacy and Safety of CB1R Inverse Agonist Taranabant in Obese Patients
Taranabant is a cannabinoid-1 receptor (CB1R) inverse agonist, that was being developed by Merck and Co., Inc. as a potential treatment of obesity.
Exposure-response analyses of tigecycline tolerability in healthy subjects
Tigecycline exposure (area under the concentration-time curve [AUC((0-infinity))] and maximum serum concentration [C(max)]) and first occurrence of nausea and vomiting were evaluated in 136 healthy subjects after...
Kerfuffle! (pt 3)
Chapter 3 of 3. Need to catch up? Read Part 1 and Part 2 of the series.
Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data
Accurate predictions of human pharmacokinetic and pharmacodynamic (PK/PD) profiles are critical in early drug development, as safe, efficacious, and "developable" dosing...
The use of gastrointestinal intubation studies for controlled release development
This review describes clinical results of gastrointestinal intubation studies of eight controlled release (CR) candidates under development during the 1990s and offer
Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients
Linezolid (Zyvox), belonging to oxazolidinone antibiotics, is commonly used for the treatment of patients infected with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Predicting pKa
One of the most important physicochemical properties of small molecules and macromolecules are the dissociation constants for any weakly acidic or basic groups...
Improving selective androgen receptor modulator discovery and preclinical evaluation
Background: Selective androgen receptor modulators (SARMs) represent a new class of pharmaceuticals that may find wide clinical use. However, selectivity is not understood...
Simulations Plus Subsidiary Receives Medicare Accreditation
Highest level of accreditation achieved after on-site inspection
Simulations Plus CEO to Present at Southern California Investor Conference
Presentation to be Webcast
Simulations Plus Releases ADMET Predictor™ Version 4.0
Latest Update to Best-in-Class Software Further Extends Lead over Competition
Simulation of Food Effect on Cilostazol Exposure in Human
For certain drugs, the time of administration respective to meal times can have a significant impact on exposure. The effect of food is usually attributed to increased solubility/dissolution rate and/or…
Simulations Plus Reports Third Quarter FY2009 Financial Results
Best-in-Class Pharmaceutical Software & Services Sales Remain Strong